Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis

Table 1 Economic model drug cost data and other economic model data

Drug cost, £⁺	ETN	INF	ADA	GOL	PSA	Ref
First 3 months	2323.75	5043.21	2288.91	2288.91	Normal	BSR guidelines [34] and MIMS [35]
Months 4-6	2323.75	2693.34	2288.91	2288.91	Normal	BSR guidelines [34] and MIMS [35]
Subsequent 3 months	2323.75	2693.34	2288.91	2288.91
Other data			Mean	SE	PSA	Ref
Change in cost for 1 U change in HAQ			106.5	69.3	Normal	Kobelt 2002 [36]
Three-month cost for mild-to-moderate psoriasis if uncontrolled by biologics			205.2	9.3	Normal	DoH 2007/2008 [37]
Three-month cost for psoriasis in remission			16.5	1	Normal	Hartman 2003 [38]
Change in HAQ while on treatment per 3-month period			0	0.02	Normal	Bojke 2011 [17] (expert elicitation)
Change in HAQ while not on treatment per 3-month period			0.018	0.007	Gamma	Bojke 2011 [17] (NOAR estimate)
Log withdrawal rate from biologics per year			-1.823	0.2044	Normal	Bojke 2011 [17] (Registers)
Probability of PsARC response on placebo			0.249	0.0384	Beta	Bojke 2011 [17] (Evidence synthesis)
Change in HAQ given a PsARC response on placebo			-0.2436	0.04746	Normal	Bojke 2011 [17] (Evidence synthesis)
Probability of PASI 75 response on placebo			0.044	0.009	Beta	Bojke 2011 [17] (Evidence synthesis)

⁺All costs inflated to 2010/11 values (£’s); ADA, Adalimumab 40 mg/2 weeks; BSR, British Society of Rheumatology; ETN, Etanercept 2×25 mg/week; INF, Infliximab 5 mg/kg/8 weeks; GOL, Golimumab 50 kg/4 weeks; HAQ, health assessment questionnaire; PsARC, Psoriatic Arthritis Response Criteria; PASI, Psoriasis Area and Severity Index; PSA, distribution used in probabilistic sensitivity analysis.

ISSN: 1471-2474